BC
NKTR icon

Bayforest Capital’s Nektar Therapeutics NKTR Stock Holding History

Bayforest Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Sell
2,260
-278
-11% -$20.3K 0.15% 249
2026
Q1 		$183K Sell
2,538
-3
-0.1% -$171 0.2% 148
2025
Q4 		$107K Buy
2,541
+862
+51% +$48.2K 0.08% 449
2025
Q3 		$95.5K Buy
+1,679
New +$55.6K 0.05% 531

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's NKTR Position: Q2 2026 in Review

Bayforest Capital reduced its Nektar Therapeutics (NKTR) stake by 11% in Q2 2026, selling an estimated $20.3K and leaving 2,260 shares worth $158K. The position accounts for 0.15% of the portfolio, ranked #249.

Bayforest Capital first reported a position in NKTR in Q3 2025 and has held it in 4 quarters since. The position peaked at $183K in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Bayforest Capital held 2,260 shares of Nektar Therapeutics worth $158K as of Q2 2026.
  • Bayforest Capital sold 278 Nektar Therapeutics shares in Q2 2026, an estimated $20.3K.
  • Nektar Therapeutics made up 0.15% of Bayforest Capital's portfolio in Q2 2026, its #249 holding.
  • Bayforest Capital first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bayforest Capital's Nektar Therapeutics position peaked at $183K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.